Marvin H. Gee is a is a researcher and entrepreneur. He the Vice President of Research for Target Discovery at 3T Biosciences, an immunotherapy company that uses machine learning to predict what chemicals would be on cancer cells that would not appear on normal ones. ^[undefined]

In 2013, Gee graduated from California Institute of Technology, earning a Bachelor's degree in Biology. Subsequently, he enrolled in Stanford University and earned his Ph.D. in Immunology in 2017. ^[1]

In December 2017, Marvin Gee joined 3T Biosciences as a co-founder.

He is also their Vice President of Research for Target Discovery.

^[1]

In 2015, Marvin Gee's patent (co-invented by David Baltimore and Michael Bethune) for domain-swap t cell receptors was accepted. ^[undefined]

In November 2017, Gee and his co-founders of 3T Biosciences Leah Sibener and Luke Lee were recognized in Forbes 30 Under 30 in 2018. They were mentioned in the 'Healthcare' sub-list. ^[undefined]